down arrow

Acasti Pharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA00430K8656
USD
3.28
0.14 (4.46%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.143.28

52 Week

1.754.96
Valuation
Technical
Day's Volume

CASH

77.43 k

Shareholding (Dec 2024)

FII

0.07%

Held by 7 FIIs

DII

97.65%

Held by 3 DIIs

Promoter

0.00%

How big is Acasti Pharma, Inc.?

22-Jun-2025

As of Jun 18, Acasti Pharma, Inc. has a market capitalization of 39.23 million, with net sales of 0.00 million and a net profit of -13.38 million over the latest four quarters. The company reported shareholder's funds of 61.74 million and total assets of 73.30 million as of Mar 24.

Market Cap: As of Jun 18, Acasti Pharma, Inc. has a market capitalization of 39.23 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Acasti Pharma, Inc. reported net sales of 0.00 million and a net profit of -13.38 million.<BR><BR>Balance Sheet Snapshot: As of Mar 24, the company reported shareholder's funds of 61.74 million and total assets of 73.30 million.

Read More

What does Acasti Pharma, Inc. do?

22-Jun-2025

Acasti Pharma, Inc. is a biopharmaceutical company specializing in the development of prescription drugs using omega-3 fatty acids from krill oil. It operates as a micro-cap company with a market cap of approximately $39.23 million and reported a net profit loss of $4 million in December 2024.

Overview: <BR>Acasti Pharma, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -4 Million (Quarterly Results - Dec 2024) <BR>Market cap: USD 39.23 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.21 <BR>Return on Equity: -24.78% <BR>Price to Book: 0.75<BR><BR>Contact Details: <BR>Address: 3009, BOUL. DE LA CONCORDE EAST, SUITE 102 LAVAL QC : H7E 2B5 <BR>Tel: 1 450 6864555 <BR>Website: https://www.acastipharma.com/

Read More

Who are in the management team of Acasti Pharma, Inc.?

22-Jun-2025

As of March 2022, Acasti Pharma, Inc.'s management team includes Dr. Roderick Carter as Independent Chairman, Ms. Janelle D'Alvise as President and CEO, and Independent Directors Mr. Jean-Marie Canan and Mr. Donald Olds.

As of March 2022, the management team of Acasti Pharma, Inc. includes Dr. Roderick Carter, who serves as the Independent Chairman of the Board, and Ms. Janelle D'Alvise, who is the President, Chief Executive Officer, and a Director. Additionally, the board features Mr. Jean-Marie Canan and Mr. Donald Olds, both serving as Independent Directors.

Read More

Is Acasti Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Acasti Pharma's technical trend is mildly bullish, with mixed indicators, but it has significantly underperformed the S&P 500, showing a year-to-date return of -16.58% compared to the S&P's 12.22%.

As of 8 September 2025, the technical trend for Acasti Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a mildly bullish stance on the weekly and a bullish stance on the monthly. However, the KST shows a mildly bearish signal on both weekly and monthly time frames. The daily moving averages are mildly bullish, and the OBV is bullish on the weekly but shows no trend on the monthly.<BR><BR>In terms of performance, Acasti Pharma has underperformed the S&P 500 across multiple periods, with a year-to-date return of -16.58% compared to the S&P 500's 12.22%, and a 5-year return of -69.95% versus the S&P 500's 96.61%. Overall, the current technical stance is mildly bullish, but the stock's performance relative to the benchmark indicates significant weakness.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 45 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.31

stock-summary
Return on Equity

-18.33%

stock-summary
Price to Book

0.70

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.44%
0%
10.44%
6 Months
16.31%
0%
16.31%
1 Year
-3.53%
0%
-3.53%
2 Years
51.85%
0%
51.85%
3 Years
664.93%
0%
664.93%
4 Years
-53.28%
0%
-53.28%
5 Years
-79.9%
0%
-79.9%

Acasti Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Acasti Pharma, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Acasti Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a mildly bullish stance on the weekly and a bullish stance on the monthly. However, the KST shows a mildly bearish signal on both weekly and monthly time frames. The daily moving averages are mildly bullish, and the OBV is bullish on the weekly but shows no trend on the monthly. In terms of performance, Acasti Pharma has underperformed the S&P 500 across multiple periods, with a year-to-date return of -16.58% compared to the S&P 500's 12.22%, and a 5-year return of -69.95% versus the S&P 500's 96.61%. Overall, the current technical stance is mildly bullish, but the stock's performance relative to the benchmark indicates significant weakness....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
7.02%
EBIT to Interest (avg)
-19.80
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.00
Tax Ratio
25.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
21.67%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.78
EV to EBIT
-1.77
EV to EBITDA
-1.77
EV to Capital Employed
0.72
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-40.80%
ROE (Latest)
-24.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (2.28%)

Foreign Institutions

Held by 7 Foreign Institutions (0.07%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -30.77% vs 35.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.10",
          "val2": "-5.00",
          "chgp": "38.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "1.40",
          "chgp": "-135.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.40",
          "val2": "-2.60",
          "chgp": "-30.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 25.58% vs 69.58% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.70",
          "val2": "-11.30",
          "chgp": "-47.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.20",
          "val2": "-4.20",
          "chgp": "176.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.60",
          "val2": "-12.90",
          "chgp": "25.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.10
-5.00
38.00%
Interest
0.00
0.00
Exceptional Items
-0.50
1.40
-135.71%
Consolidate Net Profit
-3.40
-2.60
-30.77%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -30.77% vs 35.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-16.70
-11.30
-47.79%
Interest
0.00
0.00
Exceptional Items
3.20
-4.20
176.19%
Consolidate Net Profit
-9.60
-12.90
25.58%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 25.58% vs 69.58% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Acasti Pharma, Inc. stock-summary
stock-summary
Acasti Pharma, Inc.
Pharmaceuticals & Biotechnology
Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia. CaPre is a krill oil derived mixture containing polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). CaPre is designed to reduce triglycerides while also potentially providing beneficial effects on low-density lipoprotein (LDL) cholesterol (LDL-C) and high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with severe hypertriglyceridemia.
Company Coordinates stock-summary
Company Details
3009, BOUL. DE LA CONCORDE EAST, SUITE 102 LAVAL QC : H7E 2B5
stock-summary
Tel: 1 450 6864555
stock-summary
https://www.acastipharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."